
Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata
Data from the Phase III BRAVE-AA-PEDS (NCT05723198) trial show that adolescents with severe alopecia areata (AA) administered once-daily baricitinib (Olumiant) experienced significant hair regrowth on their scalp, eyebrows, and eyelashes after 36 weeks. …